STSA-1301

N/A

Report date: 2025/11/06 17:40:12

Base Information

Drug NameSTSA-1301
Drug Alias NameSTSA-1301STSA1301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIgG receptor FcRn large subunit p51 antagonists
TargetsIgG receptor FcRn large subunit p51
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesStaidson(Beijing) Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu BioJeTay Biotechnology Co LtdStaidson(Beijing) Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A